Danielle H. Oh

Danielle H. Oh

Auto-generated profile, based on publicly available information

Danielle H. Oh

Monash Haematol, Level 3,246 Clayton Rd, Clayton, Vic 3168, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JSJake Shortt
Jake Shortt
DODanielle H. Oh
Danielle H. Oh
Stephen OpatStephen Opat
Stephen Opat
Inhibitory autoantibodies against ADAMTS13, a metalloproteinase enzyme that cleaves von Willebrand factor, are associated with the majority of nonfamilial cases of thrombotic thrombocytopenic purpura (TTP). Therapeutic plasma exchange aims to remove autoantibodies while replenishing levels of ADAMTS13.1 Adjunctive immunosuppression is often required and may include selective B-cell depletion with rituximab.1,2 Here we report a case of acute TTP in which the disease was refractory to plasma exchange and immunosuppression. Subsequent treatment with the proteasome inhibitor bortezomib resulted in a rapid clinical response associated with in vivo depletion of inhibitory autoantibodies against ADAMTS13.

3 July 2018 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
Mita MannaMita Manna
Mita Manna
RLRichard Lee-Ying
Richard Lee-Ying
GDGwynivere Davies
Gwynivere Davies
CSColin Stewart
Colin Stewart
DODanielle H. Oh
Danielle H. Oh
DSDouglas A. Stewart
Douglas A. Stewart
Although chemoimmunotherapy improves outcomes for patients with follicular lymphoma (FL), approximately 20% of patients experience early disease progression within two years of treatment and subsequently poor median survival. We conducted a retrospective study to evaluate survival rates of patients with early relapse who were treated with or without autologous transplantation. Of 517 patients with FL and who received chemoimmunotherapy, 152 relapsed and survived a minimum of four months after progression, including 84 (55.3%) with early relapse ≤2 years following initial therapy and 68 (44.7%) with later relapse. Five-year survival was superior for patients who received autologous transplantation compared to non-transplanted patients within the early relapse group (85.4% vs 57.9%, p = .001), but not within the late relapse group (p = .64). Given the limitations of a retrospective study, our study may suggest that the use of autologous transplantation for FL patients who relapse within two years of initial chemoimmunotherapy is associated with improved survival.

17 September 2012 in Medical Journal of Australia
Verified
Journal Article
Closed access
DODanielle H J Oh
Danielle H J Oh
SCShuang Quan Chan
Shuang Quan Chan
AWAndrew M Wilson
Andrew M Wilson
To the Editor: We report a case in which the concurrent administration of colchicine and simvastatin led to significant morbidity with myopathy and intestinal dysfunction. An 84-year-old man presented with an acute flare of gout, and was treated with 1 mg of colchicine daily for 3 days, and then 0.5 mg daily. His pain improved over the next 72 hours. He then noticed progressive generalised muscle ache and weakness in ...

27 March 2015 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
DODanielle H. Oh
Danielle H. Oh
NCNeil Chua
Neil Chua
LSLesley Street
Lesley Street
DSDouglas A. Stewart
Douglas A. Stewart
Although the survival rates are extremely low for patients with secondary central nervous system lymphoma (SCNSL) treated with conventional chemotherapy and radiotherapy, more encouraging outcomes have recently been reported in small series with high-dose (HD) therapy and autologous stem cell transplant (ASCT). The optimal HD regimen for SCNSL is unknown. Despite reports of thiotepa/busulfan-based conditioning for primary CNS lymphoma, very little data exist regarding the use of this regimen for SCNSL. We analyzed 23 patients with SCNSL (median age 62 years) who underwent ASCT at two Alberta centers using thiotepa, busulfan, cyclophosphamide (TBC) in six patients prior to 2011 and rituximab-busulfan, melphalan, thiotepa (R-BuMelTt) in 17 patients after 2011. At a median follow-up of 27.8 months (4.2–113.6), the 2-year actuarial rate of progression-free survival was 76.1%. In conclusion, our results demonstrate encouraging survival outcomes for patients with SCNSL treated with R-BuMelTt and ASCT.

10 September 2017 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
PWPhillip Wong
Phillip Wong
FMFrances Milat
Frances Milat
PFPeter J. Fuller
Peter J. Fuller
PKPeter G. Kerr
Peter G. Kerr
JDJames C. G. Doery
James C. G. Doery
KLKen K. Lau
Ken K. Lau

29 August 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
DODanielle H. Oh
Danielle H. Oh
XMXiao Ma
Xiao Ma
SHSimon J. Hogg
Simon J. Hogg
JHJackson He
Jackson He
CKConor Kearney
Conor Kearney
JSJake Shortt
Jake Shortt
Targeted inhibitors of bromodomain and extraterminal (BET)-bromodomains and phosphatidylinositol-3-kinase (PI3K) signaling demonstrate potent but self-limited antilymphoma activity as single agents in the context of cellular Myelocytomatosis ( cMYC ) oncogene-dysregulation. However, combined PI3K and BET inhibition imparts synergistic anticancer activity with the potential for more sustained disease responses due to the mutual antagonism of compensatory epigenetic and signaling networks. Here, we describe the mechanistic and therapeutic validation of rationally designed dual PI3K/BET bromodomain inhibitors, built by linkage of established PI3K and BET inhibitor pharmacophores. The lead candidate demonstrates high selectivity, nanomolar range cellular potency, and compelling in vivo efficacy, including curative responses in the aggressive Eµ- Myc lymphoma model. These studies further support the therapeutic strategy of combined PI3K and BET inhibition and provide a potential step-change in approach to orthogonal MYC antagonism using optimized chimeric small-molecule technology.